Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio observacional a largo plazo sobre la eficacia y seguridad de Lecigon en pacientes con enfermedad de Parkinson avanzada (ELEGANCE)

1 de octubre de 2026 actualizado por: Britannia Pharmaceuticals Ltd.

ELEGANCE: un estudio no intervencionista sobre la eficacia y seguridad a largo plazo del gel intestinal de levodopa-entacapone-carbidopa (Lecigon®) en pacientes con enfermedad de Parkinson avanzada en atención de rutina

This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).

Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing.

In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.

Descripción general del estudio

Descripción detallada

Study design:

Non-interventional study, primary data collection.

No visits or measurements will be made mandatory by the observational plan. The assignment of patients to Lecigon® not decided in advance by the study's observational plan but falls within current practice. Prescription of Lecigon® occurred before and independently of the decision to include the patient in the study.

The participating centres will offer participation in the ELEGANCE study to all patients who receive treatment with Lecigon® part of routine clinical practice. From patients, who switched to treatment with Lecigon® prior to signing of informed consent, baseline data will be collected retrospectively.

The planned non-interventional study aims to collect real-world data on the effectiveness and safety of Lecigon® as a therapy for advanced Parkinson´s Disease in routine care in Germany and Austria. The study will be expanded to additional European countries as soon as marketing authorisation in these countries and commercial stock will be available.

Primary Objectives:

  • Long-term effectiveness of Lecigon®
  • Long-term safety of Lecigon®

Secondary Objectives:

  • Patient non-motor symptoms and quality of life
  • Healthcare resource utilisation by patients

Tipo de estudio

De observación

Inscripción (Actual)

312

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Bad Segeberg, Alemania, 23795
        • Segeberger Kliniken GmbH Neurologisches Zentrum
      • Beelitz-Heilstätten, Alemania, 14547
        • Kliniken Beelitz GmbH Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson
      • Berlin, Alemania, 10117
        • Charité - Universitätsmedizin Berlin
      • Cologne, Alemania
        • Uniklinik Köln
      • Coppenbrügge, Alemania, 31863
        • Krankenhaus Lindenbrunn
      • Essen, Alemania, 45147
        • Klinik für Neurologie - Universitätsklinikum Essen
      • Freiburg im Breisgau, Alemania, 79106
        • Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie
      • Göttingen, Alemania, 37075
        • Zentrum für Seltene Erkrankungen Göttingen
      • Marburg, Alemania, 35043
        • Universitätsklinikum Giessen und Marburg
      • Oldenburg, Alemania, 26122
        • Evangelisches Krankenhaus Oldenburg
      • Osnabrück, Alemania, 49076
        • Klinikum Osnabrück GmbH Klinik für Neurologie
      • Tübingen, Alemania, 72076
        • Universitätsklinikum Tübingen
      • Ulm, Alemania, 89081
        • RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH
      • Wolfach, Alemania, 77709
        • Parkinson-Klinik Ortenau
      • Graz, Austria, 8036
        • Universitätsklinik für Neurologie, Medizinische Universität Graz
      • Hermagor, Austria, 9620
        • Abteilung für Neurologische Rehabilitation, Gailtal-Klinik
      • Innsbruck, Austria, 6020
        • Universitätsklinik für Neurologie, Medizinische Universität Innsbruck
      • Linz, Austria, 4020
        • Kepler Universitätsklinikum
      • Sofia, Bulgaria, 1113
        • Sveti Naum
      • Bruges, Bélgica, 8000
        • AZ Sint-Jan
      • Edegem, Bélgica, 2650
        • Antwerp University Hospital
      • Ghent, Bélgica
        • Ghent University Hospital
      • Liège, Bélgica
        • University Hospital Liege
      • Tournai, Bélgica, 7500
        • Centre Hospitalier de Wallonie picarde (Chwapi)
      • Brno, Chequia
        • Masaryk university
      • Olomouc, Chequia
        • Fakultní nemocnice Olomouc
      • Osijek, Croacia, 31000
        • UHC Osijek, J. Klinici za neurologiju
      • Rijeka, Croacia
        • University Hospital Centre Rijeka (KBC Rijeka)
      • Zagreb, Croacia, 10000
        • University Hospital Centre (KBC Zagreb)
      • Zagreb, Croacia, 10000
        • Klinička bolnica Dubrava
      • Copenhagen, Dinamarca, 2400
        • Bispebjerg Hospital
      • Ljubljana, Eslovenia, 1000
        • Department of Neurology, University Medical Centre
      • Maribor, Eslovenia, 2000
        • Univerzitetni klinični center Maribor
      • Barcelona, España, 08025
        • Hospital de la Santa Creu i Sant Pau
      • Madrid, España, 28040
        • Hospital Clínico San Carlos
      • Madrid, España, 28034
        • Hospital Universitario Ramón y Cajal
      • Madrid, España
        • Hospital de la Princesa
      • Seville, España, 41013
        • Hospital Virgen del Rocio
      • Budapest, Hungría
        • Semmelweis Egyetem Neurológiai Klinika Budapest
      • Pécs, Hungría, 7623
        • Pécsi Tudományegyetem Klinikai Központ Szemészeti Klinika
      • Szeged, Hungría, 6725
        • SZTE Szent-Györgyi Albert Klinikai Közpon
      • Dublin, Irlanda, D07 R2WY
        • The Dublin Neurological Institute, Mater Hospital
      • Dublin, Irlanda, D04 T6F4
        • St. Vincent's University Hospital
      • Groningen, Países Bajos, 97139713
        • University Medical Center Groningen
      • Brasov, Rumania, 500326
        • Emergency Hospital Brasov, Spitalul Clinic Județean de Urgență Brașov
      • Bucharest, Rumania, 050098
        • Bucharest University Emergency Hospital
      • Bucharest, Rumania
        • Fundeni Clinical Institute
      • Bucharest, Rumania, 011461
        • Spitalul Universitar de Urgență Elias
      • Bucharest, Rumania, 020125
        • Colentina Hospital Bucharest
      • Cluj-Napoca, Rumania, 400347
        • County Emergency Hospital Cluj-Napoca
      • Constanța, Rumania, 900591
        • County Clinical Emergency Hospital of Constanta
      • Timișoara, Rumania, 300723
        • Timiş County Emergency Clinical Hospital- Neurology 1
      • Timișoara, Rumania, 300723
        • Timiş County Emergency Clinical Hospital
      • Târgu Mureş, Rumania, 540136
        • Emergency County Hospital Targu Mures
      • Gothenburg, Suecia, 413 45
        • Sahlgrenska University Hospital
      • Lund, Suecia
        • Skånes universitetssjukhus Lund
      • Uppsala, Suecia, 751 85
        • Uppsala university hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Treating physician's normal patient pool

Descripción

Inclusion Criteria:

  • Adult Patients (18 years old and over) with Advanced Parkinson Disease already under treatment with Lecigon® (for up to 3 months before giving informed consent) in accordance with the Summary of Product Characteristics (SmPC)
  • Patients or legal representative must have signed informed consent to participate in the study
  • Patients are not taking part in another clinical (interventional) study at the same time

Exclusion Criteria:

  • Patients with contraindications as defined in the current version of the SmPC for Lecigon®
  • Patients who will not be seen again for their follow up care at the investigator's site after commencement of Lecigon® therapy
  • Patients with pump placement or pump use issues, e.g. patients with acute severe illness, patients unable to perform pump therapy, and in case of lacking compliance due to severe dementia, agitation or alcohol abuse

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: OTHER

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in OFF time from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the effectiveness of Lecigon® treatment on the change in OFF time (h/day) from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale IV Scores (MDS-UPDRS IV- motor complications)

24 months
Change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the effectiveness of Lecigon® treatment on the change in motor experiences of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale II Scores (MDS-UPDRS II - motor experiences of daily living)

24 months
Change in Daily Levodopa dose from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Daily Levodopa dose [mg/day] from baseline up to 24 months, or treatment or study discontinuation as measured by morning bolus, continuous flow, extra boli, oral doses

24 months
Usage of other Anti-Parkinsonian medicinal products from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the effectiveness of Lecigon® treatment as measured by usage of other anti-Parkinsonian medicinal products (e.g. levodopa, dopamine agonists, Monoamine Oxidase (MAO)-B inhibitors, amantadine from baseline up to 24 months, or treatment or study discontinuation

24 months
Usage of the Lecigon® pump from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the effectiveness of Lecigon® treatment use of programmed pump rate (2 or 3 rates) from baseline up to 24 months, or treatment or study discontinuation will be collected

24 months
Change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation as measured by Clinical Global Impression of Improvement Scale Score (CGI-I)

24 months
Change in Patient Global Impression of Change from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the effectiveness of Lecigon® treatment on the change in Patient Global Impression of Change (PGI-C) from baseline up to 24 months, or treatment or study discontinuation as measured by Patient Global Impression of Change Scale Score (PGI-C)

24 months
Satisfaction with treatment from baseline up to 24 months or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the effectiveness with Lecigon®, satisfaction with treatment will be assessed in terms of pump size, weight, noise, handling and overall pump satisfaction from baseline up to 24 months or treatment or study discontinuation as measured by device satisfaction scale score between 0 (absolutely unsatisfied) to 10 (absolutely satisfied) for each item.

24 months
Occurrence of AEs and SAEs from baseline up to 24 months or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the long-term safety of Lecigon® treatment Adverse Events (AEs) and Serious Adverse Events (SAEs) (including drug-related, device- and procedure-related Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs), AEs of special interest) from time of Informed consent to study completion for up to 24 months or treatment or study discontinuation will be collected

24 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on the change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation as measured by Non-Motor Symptom Scale Scores (NMSS)

24 months
Change in Sleep Quality from baseline up to 24 months, or treatment or study Discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on the change in sleep quality from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's disease sleep Scale-2 Score (PDSS-2)

24 months
Change in Activities of daily living from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on the change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale Ib Score (MDS-UPDRS Ib - non-motor experiences of daily living)

24 months
Change in Quality of Life from baseline up to 24 months or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on the change in quality of life from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's Disease Questionnaire total score (PDQ-8 or PDQ-39)

24 months
Usage of Healthcare resources from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on usage of Healthcare resources as measured by additional hospitalisation due to complications out of scope of nurse support team since the last visit

24 months

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Body weight from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Body weight (Kg) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in Blood pressure from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Blood pressure (mmHg) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in Pulse from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Pulse (bpm) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in the Liver function tests from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Liver function tests from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the full blood count from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the full blood count including B12 metabolism panel from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the ECG from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the ECG from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the Renal function tests from baseline up to 24 months, or treatment or study discontinuation
Periodo de tiempo: 24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Renal function tests from baseline up to 24 months or treatment or study discontinuation

24 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

6 de julio de 2021

Finalización primaria (Estimado)

7 de octubre de 2026

Finalización del estudio (Estimado)

7 de octubre de 2026

Fechas de registro del estudio

Enviado por primera vez

29 de julio de 2021

Primero enviado que cumplió con los criterios de control de calidad

3 de septiembre de 2021

Publicado por primera vez (Actual)

14 de septiembre de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir